Want to see SHC full AI Analyst Report?
Segment Income Breakdown
Reports operating profit for each business segment after direct costs, revealing which units generate the most profit and which are margin-challenged. Segment income shows how pricing, costs, and scale affect profitability, whether some units subsidize others, and where management can focus to improve returns or restructure. Consistent segment-level profit growth indicates stronger cash conversion to support investment and debt reduction.Sterigenics has emerged as the primary earnings engine—sustained segment-income growth driven by pricing and mix, but volumes remain timing-sensitive (maintenance/EO downtime) and require heavy capex. Nordion shows a lumpy, high‑margin ramp—outperformance boosted by harvest timing and FX tailwinds, so some quarterly strength may be transient despite structurally higher margins. Nelson Labs is the weak link: recurring volume/margin pressure compresses profitability and limits consolidated margin upside. Recent bellwether dismissals materially reduce the litigation overhang, but elevated capex and leverage above target temper near‑term free‑cash‑flow upside.
Date | Sterigenics | Nordion | Nelson Labs |
|---|---|---|---|
Jun 30, 2026 | $118.13M | $27.98M | $19.63M |
Mar 31, 2026 | $96.41M | $23.71M | $14.53M |
Dec 31, 2025 | $109.99M | $28.63M | $18.42M |
Sep 30, 2025 | $107.16M | $38.05M | $18.99M |
Jun 30, 2025 | $107.75M | $23.48M | $19.51M |
Mar 31, 2025 | $88.00M | $17.42M | $16.41M |
Dec 31, 2024 | $99.59M | $35.28M | $18.07M |
Sep 30, 2024 | $95.99M | $31.73M | $18.64M |
Jun 30, 2024 | $96.78M | $23.42M | $17.14M |
Mar 31, 2024 | $85.82M | $10.79M | $15.34M |